Replies to post #134743 on Biotech Values

[DewDiligence]

Genentech was simply smarter than Big Pharma in so many ways—#msg-16127025.

[DewDiligence]

Xenon Pharma (private) inks $646M-biobucks pain-drug-discovery deal with Roche:

http://www.fiercebiotech.com/press-releases/xenon-collaborate-genentech-discovery-novel-targeted-pain-therapeutics

Under the terms of the agreement, Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products. Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications. In addition, Xenon will receive royalties on sales of products resulting from the collaboration.

[DewDiligence]

Drug sampling and visits by pharma sales reps have declined precipitously in the past five years:



Source: http://www.ama-assn.org/amednews/2012/03/26/prl20326.htm

The above is not surprising in light of the following graphic taken from a Big Pharma webcast a few years ago: